CeriBell (NASDAQ:CBLL – Free Report) – William Blair issued their Q3 2024 earnings per share estimates for shares of CeriBell in a note issued to investors on Tuesday, November 5th. William Blair analyst M. Andrew anticipates that the company will post earnings of ($0.25) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for CeriBell’s Q4 2024 earnings at ($0.29) EPS, FY2024 earnings at ($0.99) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($1.02) EPS and FY2026 earnings at ($0.91) EPS.
Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday. They issued an “overweight” rating and a $32.00 price objective on the stock. Bank of America began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $32.00 price target on the stock. Canaccord Genuity Group began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. TD Cowen began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $31.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $31.00.
CeriBell Stock Up 4.2 %
Shares of CeriBell stock opened at $28.95 on Thursday. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.
About CeriBell
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
See Also
- Five stocks we like better than CeriBell
- What is the Dogs of the Dow Strategy? Overview and Examples
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- Stock Market Sectors: What Are They and How Many Are There?
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Buy P&G Now, Before It Sets A New All-Time High
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
